MIRM

In May 2026, Mirum reported strong first-quarter 2026 financial results with increased net product sales and raised full-year guidance, alongside positive topline results for the Volixibat VISTAS Phase 2b study and the Brelovitug Phase 2b portion of the AZURE-1 study, and in-licensed zilurgisertib for FOP. In August 2026, the company reported increased second-quarter 2026 net product sales but a wider net loss due to increased R&D and integration costs, though it again raised its full-year net product sales guidance, leading to stock pressure. September 2026 saw the U.S. FDA approval of Atebrioz (zilurgisertib) for FOP, marking Mirum's fourth commercial product, and the announcement that the primary endpoint was met in the Phase 3 AZURE-1 study of Brelovitug in chronic Hepatitis Delta Virus. In October 2026, the stock price declined following the announcement of the primary endpoint being met in the Phase 3 AZURE-1 study of Brelovitug and related investor calls. Overall, Mirum's stock gained 15.6% over the past 12 months but underperformed the market in the last year, three months, and two weeks.